Optimal index for detecting splenic involvement on 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in diffuse large B-cell lymphoma.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
medline:
2
3
2024
pubmed:
2
3
2024
entrez:
1
3
2024
Statut:
ppublish
Résumé
Accurate clinical staging is important in diffuse large B-cell lymphoma (DLBCL) to adapt to optimal therapy. Splenic involvement of DLBCL has been recently more detectable with the advancement of a diagnostic scan by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). Our clinical question is whether splenic involvement was adequately diagnosed by FDG-PET/CT imaging. This retrospective study aimed to determine the optimal index for evaluating splenic involvement in patients with DLBCL. Patients with newly diagnosed DLBCL who were examined with FDG-PET/CT at diagnosis and the end of induction chemotherapy (EOI) was enrolled. The splenic involvement with the splenic FDG uptake value higher than that of the liver at diagnosis or with the decrease of splenic uptake at EOI by visual evaluation was evaluated as positive. The calculative evaluation of splenic involvement, based on the data of standardized uptake value (SUV) of the spleen, used maximum SUV (SUVmax), mean SUV (SUVmean), spleen total lesion glycolysis (spleen TLG), and spleen length. A change in each index following induction chemotherapy was expressed as an index. Receiver operating characteristic analysis was used to set the cutoff value for each index. This study included 52 patients. Spleen TLG (0.904) showed the best accuracy, followed by SUVmax (0.885) and SUVmean (0.885), among the 5 indexes for splenic involvement at diagnosis. Splenic involvement was predicted with a higher accuracy level (0.923) when selecting the cases with values higher than the cutoff level on both spleen TLG and SUVmax. The decision at EOI was more suitable by selecting both positive cases of ∆ TLG and ∆ SUVmax. Obtaining both the positive spleen TLG and SUVmax is recommended at diagnosis to predict splenic involvement. The assessment by ∆ spleen TLG and ∆ SUVmax seems to be optimal.
Identifiants
pubmed: 38428864
doi: 10.1097/MD.0000000000037290
pii: 00005792-202403010-00023
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e37290Informations de copyright
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Saboo SS, Krajewski KM, O’Regan KN, et al. Spleen in haematological malignancies: spectrum of imaging findings. Br J Radiol. 2012;85:81–92.
Ömür O, Baran Y, Oral A, et al. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. Diagn Interv Radiol. 2014;20:185–92.
Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.
Cheson BD, Fisher RI, Barrington SF, et al. Alliance, Australasian Leukaemia and Lymphoma Group. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.
Lee HJ, Kim JW, Hong JH, et al. Cross-sectional imaging of splenic lesions: radiographics fundamentals | Online presentation. Radiographics. 2018;38:435–6.
Munakata W, Terauchi T, Maruyama D, et al. Revised staging system for malignant lymphoma based on the Lugano classification. Jpn J Clin Oncol. 2019;49:895–900.
Hwang HS, Yoon DH, Suh C, et al. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy. Ann Hematol. 2016;95:1249–58.
Shen R, Xu PP, Wang N, et al. Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. Clin Transl Med. 2020;10:e221.
de Jong PA, van Ufford HM, Baarslag HJ, et al. CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. AJR Am J Roentgenol. 2009;192:745–53.
Leite NP, Kased N, Hanna RF, et al. Cross-sectional imaging of extranodal involvement in abdominopelvic lymphoproliferative malignancies. Radiographics. 2007;27:1613–34.
Alnouby A, Ibraheem Nasr IM, Ali I, et al. F-18 FDG PET-CT Versus contrast enhanced CT in detection of extra nodal involvement in patients with lymphoma. Indian J Nucl Med. 2018;33:183–9.
Metser U, Miller E, Kessler A, et al. Solid splenic masses: evaluation with 18F-FDG PET/CT. J Nucl Med. 2005;46:52–9.
Paes FM, Kalkanis DG, Sideras PA, et al. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics. 2010;30:269–91.
Esfahani SA, Heidari P, Halpern EF, et al. Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging. 2013;3:272–81.
Seong H, Jeong YH, Lee WJ, et al. Splenic uptake on FDG PET/CT correlates with Kikuchi-Fujimoto disease severity. Sci Rep. 2021;11:10836.
Baek DW, Cho HJ, Kim JH, et al. Quantitative assessment of interim PET/CT could have more prognostic relevance than visual assessment for predicting clinical outcome of extranodal diffuse large B cell lymphoma. In Vivo. 2020;34:2127–34.
Meignan M, Gallamini A, Meignan M, et al. Report on the First International Workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50:1257–60.
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.
Rini JN, Leonidas JC, Tomas MB, et al. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med. 2003;44:1072–4.
Linguraru MG, Sandberg JK, Jones EC, et al. Assessing splenomegaly: automated volumeteric analysis of the Spleen. Acad Radiol. 2013;20:675–84.
Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507–16.
Robertson F, Leander P, Ekberg O. Radiology of the spleen. Eur Radiol. 2001;11:80–95.
Li M, Zhang L, Wu N, et al. Imaging findings of primary splenic lymphoma: a review of 17 cases in which diagnosis was made at splenectomy. PLoS One. 2013;8:e80264.
Toriihara A, Nakadate M, Nakamura S, et al. Seventy FDG-PET/CT cases in which nuclear medicine physicians suspected lymphoma: how reliable are we? Asia Ocean J Nucl Med Biol. 2017;5:95–103.
Harder FN, Jungmann F, Kaissis GA, et al. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Res. 2021;11:70.
Hu Y, Zhou W, Sun S, et al. 18F-fluorodeoxyglucose positron emission tomography-based prediction for splenectomy in patients with suspected splenic lymphoma. Ann Transl Med. 2021;9:1009.
Enke JS, Moltz JH, D’Anastasi M, et al. Radiomics features of the spleen as surrogates for CT-based lymphoma diagnosis and subtype differentiation. Cancers (Basel). 2022;14:713.
Berzaczy D, Haug AR, Raderer M, et al. Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study. PLoS One. 2019;14:e0213551.